March 3, 2005 -- After Monday’s disastrous recall of Tysabri, following two cases of a rare, but serious central nervous system disorder, Biogen Idec finds its stock trading hands for less than $40, down from $70 just two weeks ago. If the stock was fairly priced at $70, is it a bargain at $40? Or, have the financial prospects for the company changed forever, rendering it even more expensive at $40 than it was, ironically, at $70? We take a look...
